3 Annual AGILE Conference
Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment
49 International Conference on Screening for Lung Cancer th 17 Conference on Early Lung Cancer Research on Treatment th &
Venue: Invasive Medicine Center (CMI) Floor 1, Medical University of Gdańsk, Smoluchowskiego 17M, 80-214 Gdańsk, Poland Scan
March 19 - 21, 2026
Event is Open to Public In-person and Virtually
Mission Statement
The early detection of lung cancer using thoracic CT has been widely demonstrated in multiple international trials to objectively increase cure rates. Now the international focus is on effective and economical implementation. Increasingly, it is emerging that thoracic CT screening is also detecting a range of early tobacco-related diseases including cardiovascular disease and chronic obstructive pulmonary disease. These three diseases comprise the ‘BIG3’, as they collectively account for close to half of the premature deaths globally. Thoracic CT screening presents a unique opportunity to integrate care for this high risk cohort with a single imaging examination We plan to develop optimized protocols for evaluation of these major diseases, explore challenges and define solutions in enabling implementation, especially for economically disadvantaged countries across the world A core strategy in achieving this ambitious goal is to leverage the use of AI processes across the continuum of care, including its use for risk assessment, disease detection and managing disease interventions
Claudia Henschke, PhD, MD
Icahn School of Medicine at Mount Sinai New York, NY
Matthijs Oudkerk, MD, PhD University of Groningen Groningen, Netherlands
David Yankelevitz, MD
Icahn School of Medicine at Mount Sinai New York, NY
James Mulshine, MD Rush University Chicago, IL
John Field, MA, PhD, BDS, FRCPath University of Liverpool Liverpool, United Kingdom
Mario Silva, MD, PhD University of Parma Parma, Italy
Witold Rzyman, MD, PhD
Medical University of Gdańsk Gdańsk, Poland
Edyta Szurowska, MD, PhD, MBA Medical University of Gdańsk Gdańsk, Poland
15:35—16:00 16:0016:45
Thursday, March 19, 2026
16:45—17:00
17:00—17:45Introduction to Sessions
Welcome Address
Research Updates
Meeting Format
W Rzyman, M Markuszewski, J Kraszewski
C Henschke, M Oudkerk
D Yankelevitz
Session 1: Understanding Disease Burden and Integrated Screening in Eastern Europe: Established Programs and Initiatives
Moderators: M Silva, J Chorostowska-Wynimko Poland Croatia Czech Greece Hungary Serbia Slovenia
M Krzeminski
K Krpina
M Koziar-Vasakova
G Hardavela
A Kerpel-Fronius
M Cavic
M Vrankar
Session 2: Critical Considerations in Moving Towards Integrated BIG3 Screening
Moderators: J Mulshine, M Oudkerk
Natural course in the absence of screening and impact of early intervention
Lung Cancer
CVD
COPD / Emphysema
Session 2: Panel Discussion (What are the shared opportunities?)
Panelists: S Fain, V Liebenberg, S Schmidt, A Stillman, C van der Aalst
*Special Session* Details on Last Page
Session 4: Diagnostic Case Review
Moderators: M Jelitto, D Shaham
Panelists: J Gratama, E Kazerooni, A Kerpel-Fronius, K Sienkiewicz, M Silva
15:1516:00
Friday, March 20, 2026
16:0017:00
Session 5: Clinical Impact of Early Detection of Cardiovascular Disease
Moderators: A Stillman, P Raggi
Stroke and Atrial Fibrillation
Myocardial Infarction
Metabolic syndrome
Prognostic value of coronary calcium score
Session 5: Panel Discussion
Introduction
P Raggi
M van Assen
J Stojanovska
M Oudkerk
P Raggi
Panelists: J Gratama, M Jaguszewski, M van Assen, A Walstra
Session 6: AI for Early Detection of Big 3
Moderators: D Yankelevitz, M Oudkerk
Comparative AI software validation
Lung cancer: AI nodule detection and stratification
Ischemic Heart Disease: AI in CAC quantification & localization
COPD: AI in LAA Emphysema quantification and cluster characterization
Session 6: Panel Discussion
Moderators: D Yankelevitz, M Oudkerk
Introduction: Risk vs. Diagnosis
K Togka
H Lancaster
A Walstra
M Silva
R Yip
Panelists: S Fain, M Heuvelmans, E Kazerooni, L Seijo A Stillman, S Zheng
Lunch Break
Moderators: J Field, J Mulshine
Extent of Problem and Potential Benefit
Program Implementation and Challenges
Workflow Issues with Screening Implementation
Evolution of the use of risk models in lung cancer
Coffee Break
Session 8: Considerations for actionability: invasive vs. non-invasive procedures
Moderators: M Heuvelmans, L Seijo
Nonsolid
Part-solid
Solid
C Amos
V Liebenberg
S Schmidt
S Zheng
Saturday, March 21, 2026
Session 9: New Therapeutics Approaches
Moderators: C Aigner, W Rzyman
Surgery
Ablation
Immunotherapy
Chemotherapy
Radiation Therapy
M Infante
K Lau
K Kelly
N Leighl
R Dziadziuszko
F Grannis
Session 11: Monitoring Treatment Effectiveness for Stage I Lung Cancers
Moderators: M Oudkerk, L Seijo
Post-treatment Follow-up: current guidelines
Navigational bronchoscopy
Tissue acquisition
Blood test
Adjuvant therapy for stage I
Reoperate vs SBRT
(for information and submission: agile.eposter@i-dna.org)
Chairs: D Shaham, M Silva
D Yankelevitz
K Lau
E Thunnissen
J Lin
M Heuvelmans
S Senan
Session 12: Advocacy in Eastern Europe and the Potential to Collaborate
Moderators: C Healton, J Mulshine
Panelists: C Bostic, H Koong, K Przewozniak
Session 13: New Ideas, Closing Statements, and Future Meetings
C Henschke, M Oudkerk, D Yankelevitz, R Yip